Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Tempest Therapeutics Licensing Deal with Hebei Senlang Biotechnology Co., Ltd.
Tempest Therapeutics has exercised its option to obtain an exclusive license for Senlang’s CD7-targeted lentiviral in vivo CAR-T platform and associated candidates worldwide, excluding China. The deal includes the lead BCMA/GPRC5D dual-targeting candidate (TPST-4903) currently in a Phase 1 study for relapsed or refractory multiple myeloma. This exercise follows encouraging preliminary clinical data from 13 patients and expands Tempest's delivery capabilities alongside its existing LNP platform.
Counterparty
Hebei Senlang Biotechnology Co., Ltd.
“Our decision to exercise this option and obtain an exclusive license reflects our confidence in the platform and the differentiating clinical observations from the lead program.”
Matt Angel, Ph.D., President and Chief Executive Officer of Tempest
“With the addition of this clinical-stage lentiviral platform alongside our targeted LNP platform, we have expanded our capabilities to develop in vivo immune reset therapies for cancer and autoimmune disease.”
Matt Angel, Ph.D., President and Chief Executive Officer of Tempest
Vor Biopharma Licensing Deal with RemeGen Co., Ltd. Worth $10M
Vor Biopharma expanded its existing partnership with RemeGen by entering into an amended and restated license agreement to add RC298, a next-generation dual BAFF/APRIL inhibitor, to its exclusive development and commercialization rights outside of Greater China. Vor Bio will pay an upfront cash payment of $10 million and issue a pre-funded warrant for 2.3 million shares, with RemeGen eligible for up to $630 million in development and regulatory milestones plus tiered royalties.
Ocugen granted Celairis Therapeutics an exclusive license to commercialize its OCU400 gene therapy for retinitis pigmentosa in Australia, New Zealand, and ASEAN markets. Ocugen will receive up to $7.1 million in upfront and milestone payments, plus high single-digit royalties and 50% of gross profits from net sales. Ocugen retains sole manufacturing rights and expects to enter a formal supply agreement within 90 days.
Edesa Biotech granted Kyorin Pharmaceutical an exclusive license to develop and commercialize its anti-TLR4 monoclonal antibody, paridiprubart (EB05), for the treatment of ARDS in Japan. Edesa receives a $12 million upfront payment and is eligible for up to $134 million in development, regulatory, and sales milestones, plus tiered double-digit royalties. Kyorin will fund all development and commercialization activities in Japan while Edesa retains rights in all other territories.
Evommune Licensing Deal with Hinova Pharmaceuticals Inc.
Evommune announced it has entered into an exclusive license agreement with Hinova Pharmaceuticals for EVO570, an oral VAV1-directed molecular glue degrader. Evommune acquired worldwide rights (excluding Greater China) to develop, manufacture, and commercialize the candidate, which it plans to develop for rheumatoid arthritis.
Evommune Licensing Deal with Hinova Pharmaceuticals Inc. Worth $30M
Evommune has entered into an exclusive license agreement with Hinova Pharmaceuticals to develop and commercialize EVO570, a VAV1 molecular glue degrader, globally excluding Greater China. Evommune will pay $20 million upfront in cash and $10 million in pre-funded warrants, with Hinova eligible for up to $1.07 billion in additional milestone payments plus tiered royalties.
Kiora Pharmaceuticals entered into an exclusive license agreement with Senju Pharmaceutical to develop and commercialize KIO-401, a late-stage oral small-molecule calpain inhibitor for ophthalmic diseases, in all territories outside of Asia. Kiora will pay an upfront fee of $3.5 million, low teen millions upon technology transfer, and up to $168.5 million in potential regulatory and commercial milestones, plus single-digit royalties.
Tempus AI Licensing Deal with Bristol-Myers Squibb Company Worth $192M
Tempus AI entered into a series of agreements with Bristol-Myers Squibb (BMS) and Pathos AI to expand the use of its de-identified multimodal real-world data and analysis tools. The deal provides for aggregate cash payments to Tempus of $192.5 million over approximately five years, including $137.5 million for oncology data services to BMS and $55 million for neurology data and agentic tools to Pathos to support BMS's therapeutic development.
Zymeworks entered into a global collaboration and license agreement with Roche for the development and commercialization of ZW209, a trispecific T-cell engager targeting DLL3. Zymeworks will receive a $55 million upfront payment and a $40 million milestone upon Phase 1b trial initiation, with eligibility for up to $718 million in additional milestones plus tiered royalties.
DataMeds AI Licensing Deal with REBOOT Health AI, Inc. Worth $2M
DataMeds AI, Inc. entered into an exclusive intellectual property license agreement with REBOOT Health AI to use its AI platform for DataMeds' GLP-1 weight management business. As consideration, DataMeds will issue 666,667 shares of common stock with a guaranteed minimum value of $2 million after 180 days, plus a revenue-sharing arrangement. The company also disclosed it remains below Nasdaq's minimum stockholders' equity requirement for continued listing.
RYTHM, Inc.'s subsidiary VCP IP Holdings amended its licensing agreement with Green Thumb Industries' subsidiary GTI Core to add the Señorita brand to the licensed intellectual property. In exchange for the additional rights, the base licensing fees paid to RYTHM will increase by $250,000 per year.
Biohaven Licensing Deal with Ono Pharmaceutical Co., Ltd. Worth $100M
Biohaven granted Ono Pharmaceutical an exclusive license to develop and commercialize its MoDE pan IgG degrader portfolio, including lead candidate BHV-1300, in Japan, South Korea, Taiwan, and ASEAN countries. Biohaven receives an $80 million upfront payment and is eligible for a $20 million milestone payment plus royalties of approximately 20% on net sales in the territory.
Ocugen Licensing Deal with Roots Pharmaceutical Company WLL Worth $259M
Ocugen granted Roots Pharmaceutical an exclusive license to commercialize OCU400, a modifier gene therapy for retinitis pigmentosa, in the Middle East and North Africa. Ocugen will receive up to $4 million in upfront and development milestones, up to $255 million in sales milestones, and a 22% royalty on net sales. Ocugen also entered into a commercial supply agreement to manufacture the product for Roots.
Aquestive Therapeutics Licensing Deal with Eton Pharmaceuticals, Inc. Worth $57.5M
Aquestive Therapeutics granted Eton Pharmaceuticals exclusive U.S. rights to commercialize LIBERVANT (diazepam) buccal film for the treatment of seizure clusters in epilepsy patients. Aquestive received a $10 million upfront fee and is eligible for up to $47.5 million in regulatory and commercial milestones, plus mid-teens royalties on net sales. Aquestive will remain the exclusive manufacturer and supplier of the product for an initial 20-year term.
BioNexus Gene Lab Licensing Deal with Ruanyun Edai Technology Inc. Worth $3.5M
BioNexus Gene Lab Corp. entered into an exclusive 10-year licensing agreement with Ruanyun Edai Technology Inc. (RYET) for the CogniAI document-intelligence platform in the Malaysian healthcare sector. The company will issue 410,000 shares to satisfy the $3.5 million license consideration and an additional 150,000 shares in exchange for 500,000 RYET ordinary shares. BioNexus intends to use the platform to target Malaysia's RM1 billion public healthcare digitalization program.
Netlist Licensing Deal with Micron Technology, Inc Worth $600M
Netlist entered into a five-year patent license and settlement agreement with Micron Technology, resolving all pending legal proceedings between the companies. Micron will pay Netlist $30 million per quarter through Q3 2031, totaling $600 million, and will also purchase 10 million shares of Netlist common stock for $1 million.
Aviat Networks Licensing Deal with Dixon Electro Appliances Private Ltd.
Aviat Networks, through its subsidiary, entered into an intellectual property license agreement with Dixon Electro Appliances Private Ltd. (DEAPL) to manufacture and sell WTM 4000 microwave radios in India. The partnership allows Aviat to address the 'Made in India' market requirements while retaining its IP and providing software and services, targeting an estimated demand of 250,000 links over the next four years.
Alector Licensing Deal with Genentech, Inc. Worth $100M
Alector entered into an exclusive global licensing agreement with Genentech to develop and commercialize AL050, a brain-penetrant engineered GCase enzyme replacement therapy for Parkinson’s disease. Alector will receive a $100 million upfront payment and is eligible for up to $1.17 billion in additional milestone payments plus tiered royalties on net sales. The deal extends Alector's cash runway into 2029 while allowing the company to retain ownership of its proprietary Alector Brain Carrier platform.
DarkPulse Licensing Deal with Department of the Air Force, Air Force Research Laboratory
DarkPulse, Inc. has executed an exclusive U.S. patent license agreement with the U.S. Air Force Research Laboratory for a package of six patents. The licensed technologies cover satellite power-sharing, laser systems, constellation navigation, and hybrid terrestrial-satellite networking, which the company intends to use to develop a space-based power grid.
Counterparty
Department of the Air Force, Air Force Research Laboratory
Take Two Interactive Software Licensing Deal with Microsoft Corporation
Take-Two Interactive Software entered into a new long-term XBOX Publisher License Agreement with Microsoft, effective September 17, 2026. The agreement grants Take-Two the rights to develop, publish, and distribute XBOX-compatible products across all Microsoft devices in exchange for wholesale payments and revenue sharing. This new agreement supersedes all previous publisher license agreements between the two companies.
Biomarin Pharmaceutical Licensing Deal with Ascendis Pharma A/S
BioMarin entered into a definitive Settlement and License Agreement with Ascendis Pharma, granting Ascendis a non-exclusive worldwide license to certain patents for the commercialization of TransCon CNP (navepegritide). In exchange, BioMarin will receive royalties of 20% on net sales in the U.S. and 18% in the EU, Brazil, and South Korea through May 2030, while both parties agreed to dismiss all pending patent litigation.
Cboe Global Markets Licensing Deal with S&P Opco, LLC
Cboe Global Markets has signed a 25-year extension of its exclusive licensing agreement with S&P Dow Jones Indices, securing the rights to list and trade S&P 500 index options through 2051. The agreement updates royalty fee terms starting in 2027 on a per-contract basis and includes cross-licenses for Volatility Indices (VIX) and other intellectual property. Management expects the updated fee structure to have a de minimis impact on 2027 net revenue growth relative to organic volume increases.
Heron Therapeutics Licensing Deal with Long Grove Pharmaceuticals, LLC
Heron Therapeutics entered into a multi-product Development and License Agreement with Long Grove Pharmaceuticals and Capstone Development Services. The agreement grants Heron an exclusive license to import, distribute, and market certain products in the U.S. in exchange for regulatory milestones, sales-based milestones, and royalty payments.
Keros Therapeutics Licensing Deal with Takeda Pharmaceuticals U.S.A., Inc. Worth $20M
Keros Therapeutics announced it will receive a $20 million development milestone payment from its partner Takeda following the dosing of the first patient in the Phase 3 ELRiSE MF clinical trial for elritercept. The payment is part of a global license agreement that includes potential milestones exceeding $1.1 billion. Keros intends to distribute 25% of the net cash proceeds from this milestone to its stockholders.
Ainos Licensing Deal with BioPhoenix Co., Ltd. Worth $10M
Ainos entered into a global exclusive license agreement with BioPhoenix for its VELDONA low-dose oral interferon alpha technology platform for Sjögren’s Disease and Thrombocytopenia. Ainos will receive an upfront fee of $600,000 and is eligible for up to $10.0 million in total fees if additional indications are licensed, plus 25% of net sublicensing revenue. BioPhoenix will assume all clinical and regulatory funding and execution for the licensed indications.
Interparfums has entered into an exclusive, worldwide license agreement with PUMA for the creation, development, production, and distribution of fragrances under the PUMA brand. The agreement runs through December 31, 2037, with the company planning to launch a new signature lifestyle fragrance in 2027.
Recursion Pharmaceuticals Licensing Deal with Tempus AI, Inc. Worth $12M
Recursion Pharmaceuticals granted Tempus AI a non-exclusive license to its TxFM RNA sequencing model for use in oncology in exchange for a $12 million license fee. Simultaneously, the parties amended an existing master agreement to extend its term to six years and restructure annual license fees, while Recursion gained access to additional de-identified pathology records.
Interparfums and Marquee Brands have signed a 20-year extension of their exclusive worldwide license agreement for Roberto Cavalli and Just Cavalli fragrances, extending the partnership through December 31, 2046. The deal covers the continued creation, development, and distribution of fragrances globally following the successful 2025 launch of the Serpentine blockbuster fragrance.